作为心脏保护剂的布图衍生物的设计,合成和生物评估
Yuan Liu1, Fa-Qi Wang1, Xin-Hao Hua1
1Department of Pharmacy Engineering, Tianjin University of Technology, Tianjin, 300384, People's Republic of China.
Natural products and bioprospecting
|February 5, 2025
概括
新的布图丁衍生物显示出对心血管药物开发的前景. 几种化合物显示出对心肌细胞损伤的显著保护和NHE-1的特定抑制,为新型心脏保护剂铺平了道路.
科学领域:
- 药用化学 医学化学
- 心血管药理学心血管药理学
- 药物发现 药物发现 药物发现
背景情况:
- 天然产品对于开发心血管药物至关重要.
- 布图衍生物的治疗潜力正在被探索.
- 心肌细胞损伤和NHE-1活动是心血管疾病的关键目标.
研究的目的:
- 设计,合成和评估用于抑制NHE-1和心脏保护作用的新型布丁衍生物.
- 确定结构-活性关系 (SAR) 以优化药理作用.
- 探索胺 - 瓜尼丁基心脏保护剂的潜在新途径.
主要方法:
- 使用NMR和HR-ESI-MS.合成和结构确认29个布丁衍生物.
- 对H9c2心肌细胞损伤的保护作用的评估.
- 评估NHE-1抑制活性和特异性.
- 分子建模研究 (CDOCKER) 用于预测结合相互作用.
主要成果:
- 化合物9d,9f,9k,9m和9n对心肌细胞损伤具有显著的保护 (>30%),表现优于对照组.
- 化合物9k,9m和9o显示出显著的NHE-1抑制 (dpHi/分钟<0.23) 具有高特异性.
- 分子建模表明9m和9o与NHE-1的良好相互作用,显示CDOCKER能量低于对照.
- SAR研究确定了胺基组,四碳链体和偏氧环作为关键的药理物.
结论:
- 新型布丁衍生物具有强大的心脏保护和NHE-1抑制活性.
- 特定的结构特征对于增强这些药理作用至关重要.
- 这些发现支持开发新的基于胺-瓜尼丁的心脏保护药物.
相关概念视频
01:28Structure-Activity Relationships and Drug Design
493
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
493
01:16Antianginal Drugs: Nitrates and β-Blockers
509
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
509
01:26Heart Failure Drugs: Inotropic Agents
505
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
505
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
404
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
404
01:22Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311